Nonsteroidal anti-inflammatory agents after argon laser trabeculoplasty. A trial with flurbiprofen and indomethacin.

Seventy glaucomatous eyes received argon laser trabeculoplasty (ALT) to 180 degrees of the trabecular meshwork. Thirty-six eyes were treated with topical .03% sodium flurbiprofen, a nonsteroidal anti-inflammatory agent; 34 eyes received placebo. Eighteen eyes received ALT to 360 degrees of the meshwork; nine of these eyes were treated with topical 1% indomethacin and nine eyes received placebo. Eyes treated with flurbiprofen and indomethacin showed significantly less conjunctival injection following ALT. However, these agents did not significantly alter the anterior chamber reaction after laser therapy compared to placebo. Flurbiprofen-treated eyes showed a significantly smaller percent (32.6%) decrease in intraocular pressure (IOP) one day after ALT as compared to eyes receiving placebo (43.8%). In addition, a higher percentage of placebo treated eyes had a fall in IOP of at least 10 mmHg up to five weeks after ALT. Within the indomethacin protocol, the percentage change in IOP was comparable for both indomethacin and placebo treated eyes. Mild ocular symptoms (itching, burning, foreign-body sensation) developed in 77.8% of flurbiprofen-treated eyes, in 55.6% of indomethacin-treated eyes, and in 20.9% of eyes receiving placebo.

RCT Entities:   Population Interventions Outcomes